Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MDS 2021 | Immune dysregulation and drug selection in MDS

Shahram Kordasti • 27 Jan 2021
ESH MDS 2021
Myelodysplastic Syndromes

Shahram Kordasti, MD, PhD, King’s College London, London, UK, discusses the ‘immunological mess’, or immune dysregulation, associated with myelodysplastic syndromes (MDS) at ESH MDS 2021. Dr Kordasti describes how inflammatory and cellular responses vary between patients, making drug selection challenging. Furthermore, he highlights the need to develop a system of stratifying and selecting MDS patients to optimize drug selection. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.

More from Shahram Kordasti

2:06
Understanding the role of inflammation and the immunome in MDS pathophysiology
Shahram Kordasti • 5 Apr 2024
2:53
Immune checkpoint inhibitors in MDS: the i4MDS consortium
Shahram Kordasti • 5 Apr 2024
4:27
The role of immune checkpoint inhibitors in MDS
Shahram Kordasti • 22 Sep 2021
6:05
The immune system's role in higher-risk MDS
Shahram Kordasti • 22 Sep 2021

Related Videos

1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
4:25
The challenges with accurately diagnosing and risk-stratifying patients with MDS
Klaus Metzeler • 16 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals